Key Takeaways
- Shares of Tyra Biosciences plummeted 22% to $20.96 following underwhelming Phase 2 clinical trial results for its experimental bladder cancer medication dabogratinib
- The treatment achieved a 64% complete response rate at the 60mg dosage level, falling short of the critical 70% threshold Wall Street analysts established for success
- The drug demonstrated a clean safety profile, with no serious Grade 4-5 adverse events recorded and zero dose reductions necessary at the 60mg level
- The company intends to explore a higher 70mg dosage in an upcoming patient cohort while advancing the compound into pivotal late-stage clinical trials
- Competitor UroGen Pharma (URGN) saw shares climb 5.6% as its rival bladder cancer therapy Zusduri benefited from the disappointing results
Shares of Tyra Biosciences plunged 22% to $20.96 during Wednesday’s trading session after the company unveiled Phase 2 clinical data for dabogratinib, its oral bladder cancer candidate, that failed to meet Wall Street’s performance expectations.
The SURF302 Phase 2 clinical study evaluated dabogratinib in a population of 44 adult patients diagnosed with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. While the experimental therapy achieved a 79% overall response rate, it only reached a 64% best overall complete response rate when administered at 60mg once daily.
The critical issue? Financial analysts from both Piper Sandler and H.C. Wainwright had previously established 70% as the minimum acceptable threshold for clinical success. The 64% outcome represents a notable shortfall versus that established benchmark.
Piper Sandler maintained an Overweight investment rating alongside a $56 price target heading into the data release. The investment firm had projected this specific bladder cancer application could represent an addressable market exceeding $1 billion for the medication.
Complicating matters, the stock had appreciated approximately 13% during the trading week preceding the data announcement, suggesting investors had already incorporated expectations of positive results into the share price. This pre-data rally amplified the subsequent selloff.
Regarding tolerability, the drug performed well. The majority of adverse reactions were classified as Grade 1 or 2 in severity, with zero Grade 4 or 5 events documented, and no patients required dose reductions or discontinued therapy due to treatment-related issues at the 60mg dosing level.
The Path Forward for Dabogratinib
Tyra has no intention of abandoning the development program. Company leadership announced plans to evaluate a higher 70mg dose in a fresh study cohort while simultaneously progressing dabogratinib toward late-stage pivotal trials.
Chief Executive Officer Todd Harris emphasized the medication’s potential to become the first once-daily oral therapeutic option in this specific cancer indication. Chief Medical Officer Doug Warner confirmed the company’s commitment to advancing the program into registrational-phase development.
Jones Trading equity analyst Boris Peaker indicated the results don’t warrant terminating the program entirely, though he cautioned that pursuing the 70mg dose escalation “will come at the cost of additional safety concerns.”
Certain analysts had previously raised concerns that an oral pill formulation might not deliver sufficient drug concentration directly to bladder tissue to effectively compete with catheter-based direct instillation approaches. Wednesday’s clinical data appeared to validate those early reservations.
Competitive Landscape Shifts
The disappointing data provided a tailwind for UroGen Pharma, whose prescription chemotherapy treatment Zusduri utilizes direct catheter-based delivery. URGN shares advanced 5.6% during Wednesday’s session.
Johnson and Johnson maintains a presence in this therapeutic space with Erda-iDRS, an investigational drug delivery platform engineered to release the targeted kinase inhibitor erdafitinib directly into bladder tissue over a three-month duration.
Broader market conditions provided no support for Tyra on Wednesday. The S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all posted modest declines during pre-market activity, with investor sentiment dampened following a stronger-than-anticipated August employment report that sparked renewed uncertainty regarding the Federal Reserve’s upcoming policy decisions.
During pre-market trading, TYRA shares had declined as much as 31.1% to $18.42 before staging a partial recovery by the official market open.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
